Latest posts by Lancet Global Health (see all)
- [Articles] Measuring Iran’s success in achieving Millennium Development Goal 4: a systematic… - Mar. 29, 2017
- [Comment] Achieving equity in maternal health in China: more to be done - Mar. 25, 2017
- [Articles] Progress and challenges in maternal health in western China: a Countdown to 2015… - Mar. 22, 2017
- [Corrections] Correction to 2016; 5: e392–93 - Mar. 17, 2017
The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% effectiveness against disease has been demonstrated for VSV-EBOV, a vaccine based on a replicating vesicular stomatitis virus genetically modified to express Ebola virus glycoprotein.2 This vaccine has been granted Breakthrough Therapy Designation status by the US Food and Drug Administration and PRIME status by the European Medicines Agency, and its single-dose regimen and proof of effectiveness from 10 days post-immunisation make it an attractive candidate for use in a responsive campaign (whether it be through ring immunisation around identified cases or as a whole-population intervention).